CA3034211A1 - Piperazine derivatives, pharmaceutical compositions and methods of use thereof - Google Patents
Piperazine derivatives, pharmaceutical compositions and methods of use thereof Download PDFInfo
- Publication number
- CA3034211A1 CA3034211A1 CA3034211A CA3034211A CA3034211A1 CA 3034211 A1 CA3034211 A1 CA 3034211A1 CA 3034211 A CA3034211 A CA 3034211A CA 3034211 A CA3034211 A CA 3034211A CA 3034211 A1 CA3034211 A1 CA 3034211A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cancer
- use according
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376396P | 2016-08-18 | 2016-08-18 | |
| US62/376,396 | 2016-08-18 | ||
| PCT/IL2017/050909 WO2018033918A1 (en) | 2016-08-18 | 2017-08-17 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3034211A1 true CA3034211A1 (en) | 2018-02-22 |
Family
ID=61196523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3034211A Pending CA3034211A1 (en) | 2016-08-18 | 2017-08-17 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11084807B2 (https=) |
| JP (1) | JP7471818B2 (https=) |
| CN (1) | CN109641884B (https=) |
| AU (1) | AU2017311691B2 (https=) |
| CA (1) | CA3034211A1 (https=) |
| WO (1) | WO2018033918A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084807B2 (en) * | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
| US10682346B2 (en) | 2016-11-07 | 2020-06-16 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses |
| EP4464334A3 (en) | 2016-11-07 | 2025-01-08 | VIDAC Pharma Ltd. | Use of compounds for treating hk2-expressing cancers |
| EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | INFLAMMATION TREATMENT COMPOSITIONS AND METHODS |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| WO2025163633A1 (en) * | 2024-01-30 | 2025-08-07 | Vidac Pharma Ltd. | Synergistic therapies for treating cancer |
| CN118063410B (zh) * | 2024-03-04 | 2026-03-13 | 河南省锐达医药科技有限公司 | 一种哌嗪萘甲酰胺类化合物、其制备方法及应用 |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2742472A (en) | 1956-04-17 | Spasmolytic pipergzjnes | ||
| FR6541E (fr) | 1906-12-17 | Paul Charles Louis Aime Joseph | Chambre d'encolleuse économique à grande production | |
| BE486462A (https=) | ||||
| NL71566C (https=) | 1948-10-30 | |||
| GB666457A (en) | 1948-10-30 | 1952-02-13 | Henri Morren | Carbonyl chlorides and monocarboxyamides of piperazine and process for the preparation thereof |
| GB748812A (en) | 1952-12-15 | 1956-05-09 | Abbott Lab | Improvements in or relating to piperazine derivatives and process of preparing the same |
| CH333366A (de) | 1953-09-04 | 1958-10-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyridazone |
| DE954155C (de) | 1954-01-08 | 1956-12-13 | Schering Ag | Verfahren zur Herstellung von 4-Aminochromanen |
| GB773756A (en) | 1954-08-18 | 1957-05-01 | Searle & Co | 9-aminoalkyl-9-xanthenecarboxamides and derivatives thereof |
| GB781528A (en) | 1954-09-10 | 1957-08-21 | American Cyanamid Co | Substituted ethylene dipiperazines |
| GB778309A (en) | 1954-11-12 | 1957-07-03 | Rhone Poulenc Sa | 4-o.o-diphenyl-phosphorylamido-pyrazolones |
| NL92955C (https=) | 1954-12-23 | |||
| GB777209A (en) | 1954-12-28 | 1957-06-19 | Wellcome Found | Improvements in or relating to piperazine derivatives |
| US2838509A (en) | 1956-10-02 | 1958-06-10 | Searle & Co | 9-aminoalkyl-9-xanthenecarboxamides |
| FR1192168A (fr) | 1957-04-11 | 1959-10-23 | Préparation de la nu-thiodiphénylcarbamyl piperazine | |
| US2887481A (en) | 1957-04-29 | 1959-05-19 | Schering Corp | Heterocyclic amides |
| US3284449A (en) | 1964-12-29 | 1966-11-08 | Searle & Co | Hydrazones of 1-amino-4-xanthenecar-bonylpiperazines |
| NL129629C (https=) | 1965-07-02 | |||
| FR6541M (https=) | 1967-05-10 | 1968-12-16 | ||
| US3700658A (en) | 1967-07-05 | 1972-10-24 | Adolf Steinhofer | N-alkyl-n-arylcarbamoyl lactams |
| US3585171A (en) | 1967-07-05 | 1971-06-15 | Basf Ag | Accelerating the anionic polymerization of lactams |
| DE1720281A1 (de) | 1967-07-05 | 1971-06-09 | Basf Ag | Verfahren zum Beschleunigen der anionischen Polymerisation von Lactamen |
| DE1770968A1 (de) | 1968-07-24 | 1972-01-13 | Bayer Ag | Verfahren zur Herstellung von Polyamiden |
| GB1282336A (en) | 1970-03-25 | 1972-07-19 | Rech S Et D Applic Scient Soge | Thiaxanthene derivatives and their preparation |
| US3803141A (en) | 1972-08-14 | 1974-04-09 | Burdick & Jackson Labor Inc | 10-(1-substituted-3-pyrrolidylmethyl)phenothiazines |
| US3838118A (en) * | 1973-02-20 | 1974-09-24 | Janssen Pharmaceutica Nv | ((thioxanthenyl)propyl)-piperidyl-benzimidazolinones |
| FR2218100A1 (en) * | 1973-02-20 | 1974-09-13 | Janssen Pharmaceutica Nv | Neuroleptic tricyclic derivs. - of benzimidazolinones and triazaspiro-4,5-decan-4-ones |
| DE2519583A1 (de) | 1975-05-02 | 1976-11-18 | Basf Ag | Thermoplastische polybutylenterephthalat-formmassen |
| JPS5334779A (en) | 1976-09-09 | 1978-03-31 | Kissei Pharmaceut Co Ltd | Novel piperazine derivatives and thier preparation |
| US4188485A (en) | 1978-06-16 | 1980-02-12 | G. D. Searle & Co. | 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds |
| CH653675A5 (en) | 1983-05-26 | 1986-01-15 | Ciba Geigy Ag | Microbicides |
| DE3607194A1 (de) | 1986-03-05 | 1987-09-10 | Merck Patent Gmbh | Carbamoylphenothiazine |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| US5223508A (en) | 1988-12-27 | 1993-06-29 | Kirin Beer Kabushiki Kaisha | Pyridyl carboximidamide compounds useful in treating blood pressure |
| JPH03251564A (ja) * | 1990-02-26 | 1991-11-11 | Taisho Pharmaceut Co Ltd | ジメチルカルバゾール誘導体 |
| JPH04130429A (ja) | 1990-09-21 | 1992-05-01 | Konica Corp | ハロゲン化銀写真感光材料 |
| JP2696434B2 (ja) | 1991-01-23 | 1998-01-14 | 富士写真フイルム株式会社 | 画像形成方法 |
| JPH04356466A (ja) | 1991-01-28 | 1992-12-10 | Mitsui Toatsu Chem Inc | 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤 |
| JPH05273701A (ja) | 1992-03-26 | 1993-10-22 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| JPH06211664A (ja) | 1993-01-20 | 1994-08-02 | Pola Chem Ind Inc | 薬剤に対する感受性回復剤 |
| US5599815A (en) | 1993-02-04 | 1997-02-04 | Meiji Seika Kabushiki Kaisha | Antipsychotic benzoisothiazolyl piperazine derivatives |
| JPH06228095A (ja) | 1993-02-04 | 1994-08-16 | Kirin Brewery Co Ltd | カルバゾール誘導体 |
| WO1994022842A1 (en) | 1993-03-29 | 1994-10-13 | Basf Aktiengesellschaft | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
| DE69422306T4 (de) | 1993-11-30 | 2000-09-07 | G.D. Searle & Co., Chicago | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US6071901A (en) * | 1994-01-04 | 2000-06-06 | Novo Nordisk A/S | Substituted dibenz[b,f]azepines and uses thereof |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| JPH08110621A (ja) | 1994-10-12 | 1996-04-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー感光材料 |
| JPH08217758A (ja) | 1995-02-09 | 1996-08-27 | Nissan Chem Ind Ltd | ４−ハロアルキルピリミジン−５−カルボン酸アニライド誘導体 |
| UA54385C2 (uk) * | 1995-04-07 | 2003-03-17 | Ново Нордіск А/С | N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування |
| US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| WO1997046549A1 (en) | 1996-06-05 | 1997-12-11 | Novartis Ag | Anti-neurodegeneratively effective xanthene derivatives |
| JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
| JPH11292840A (ja) | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
| TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| EP1236726B1 (en) | 1999-12-03 | 2004-12-01 | Ono Pharmaceutical Co., Ltd. | Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient |
| US6436972B1 (en) | 2000-04-10 | 2002-08-20 | Dalhousie University | Pyridones and their use as modulators of serine hydrolase enzymes |
| GB0012362D0 (en) | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| CA2310205A1 (en) | 2000-05-29 | 2001-11-29 | Dalhousie University | Unknown |
| DE10035928A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| JP2002047272A (ja) | 2000-07-26 | 2002-02-12 | Dai Ichi Seiyaku Co Ltd | ポリアミンアミド誘導体 |
| CA2418720A1 (en) | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| AU2003225088A1 (en) | 2002-04-19 | 2003-11-03 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| UA79286C2 (en) * | 2002-06-29 | 2007-06-11 | Zentaris Gmbh | Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| US20040147502A1 (en) | 2002-12-17 | 2004-07-29 | Bisacchi Gregory S. | Beta lactam compounds and their use as inhibitors of tryptase |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP2335701B1 (en) | 2003-12-15 | 2012-07-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| WO2005111025A1 (en) | 2004-04-29 | 2005-11-24 | Aventis Pharmaceuticals Inc. | 3-piperidinylisochroman-5-ols as dopamine agonists |
| CA2567080A1 (en) | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| GB0500300D0 (en) | 2005-01-07 | 2005-02-16 | Ionix Pharmaceuticals Ltd | Chemical compositions |
| WO2006105056A2 (en) | 2005-03-28 | 2006-10-05 | Fmc Corporation | Insecticidal 2,4-diaminoquinazolines and related derivatives |
| DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| EP1960364A2 (en) | 2005-12-07 | 2008-08-27 | Ramot at Tel-Aviv University Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| WO2007098086A2 (en) | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| GB0614365D0 (en) | 2006-07-19 | 2006-08-30 | Proaxon Ltd | Pharmaceutical compositions and their use |
| AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
| EP2060563A4 (en) | 2006-09-08 | 2010-12-22 | Dainippon Sumitomo Pharma Co | CYCLIC AMINO ALKYL CY CARBOXYL AMIDE DERIVATIVE |
| RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| US8202891B2 (en) | 2007-04-24 | 2012-06-19 | Theravance, Inc. | Quaternary ammonium compounds useful as muscarinic receptor antagonists |
| JP2011504499A (ja) | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
| US8017617B2 (en) | 2007-12-14 | 2011-09-13 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP5538239B2 (ja) | 2008-02-12 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンゾモルファン及び関連骨格の尿素誘導体、そのような化合物を含む医薬ならびにそれらの使用 |
| EP2334680A2 (en) | 2008-08-20 | 2011-06-22 | Sequoia Pharmaceuticals, Inc. | Hcv protease inhibitors |
| EP2411526A4 (en) | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF GANGLIOSID BIOSYNTHESIS |
| WO2010137738A1 (en) | 2009-05-28 | 2010-12-02 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compounds for the treatment of stress-related conditions |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| TW201236239A (en) | 2010-11-16 | 2012-09-01 | Solvay | Rechargeable metal or metal-ion cell |
| JP2012111731A (ja) | 2010-11-26 | 2012-06-14 | Otsuka Pharmaceut Co Ltd | 医薬 |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| CN102690717B (zh) | 2011-03-24 | 2014-08-20 | 中国石油化工股份有限公司 | 一种极压长寿命汽轮机润滑油组合物 |
| CA2830958A1 (en) | 2011-04-06 | 2012-10-11 | The Scripps Research Institute | N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2015005901A1 (en) | 2013-07-09 | 2015-01-15 | Bristol-Myers Squibb Company | Combinations of hepatitis c virus inhibitors |
| CN103896990B (zh) | 2014-03-12 | 2017-02-08 | 石家庄诚志永华显示材料有限公司 | 有机电致发光材料及其应用 |
| CN104109134A (zh) | 2014-06-26 | 2014-10-22 | 陕西科技大学 | 一种n-酰基吩噻嗪及其制备方法 |
| CN104109133A (zh) | 2014-06-26 | 2014-10-22 | 陕西科技大学 | 一种制备n-酰基吩噻嗪的方法 |
| CN104497013B (zh) | 2014-12-11 | 2017-05-31 | 石家庄诚志永华显示材料有限公司 | 氮杂咔唑类oled材料及其制备方法与应用 |
| CN104557875A (zh) | 2015-01-21 | 2015-04-29 | 石家庄诚志永华显示材料有限公司 | 茚并吲哚环状化合物与在有机发光二极管中的应用 |
| US11084807B2 (en) * | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
| EP4464334A3 (en) * | 2016-11-07 | 2025-01-08 | VIDAC Pharma Ltd. | Use of compounds for treating hk2-expressing cancers |
| US10682346B2 (en) | 2016-11-07 | 2020-06-16 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses |
-
2017
- 2017-08-17 US US15/735,183 patent/US11084807B2/en active Active
- 2017-08-17 CA CA3034211A patent/CA3034211A1/en active Pending
- 2017-08-17 AU AU2017311691A patent/AU2017311691B2/en active Active
- 2017-08-17 WO PCT/IL2017/050909 patent/WO2018033918A1/en not_active Ceased
- 2017-08-17 JP JP2019506346A patent/JP7471818B2/ja active Active
- 2017-08-17 CN CN201780050775.1A patent/CN109641884B/zh active Active
-
2021
- 2021-08-08 US US17/396,707 patent/US12162868B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018033918A1 (en) | 2018-02-22 |
| US20220098179A1 (en) | 2022-03-31 |
| US11084807B2 (en) | 2021-08-10 |
| JP7471818B2 (ja) | 2024-04-22 |
| AU2017311691B2 (en) | 2021-12-02 |
| US20200031815A1 (en) | 2020-01-30 |
| JP2019524789A (ja) | 2019-09-05 |
| AU2017311691A1 (en) | 2019-04-04 |
| US12162868B2 (en) | 2024-12-10 |
| CN109641884A (zh) | 2019-04-16 |
| CN109641884B (zh) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162868B2 (en) | Piperazine derivatives, pharmaceutical compositions and methods of use thereof | |
| CN103140479B (zh) | 制造嘧啶衍生物的方法 | |
| JP2013199483A (ja) | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 | |
| JP2023002688A (ja) | ＮｏｔｃｈシグナリングのエンハンサーならびにＮｏｔｃｈのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用 | |
| CN111410661A (zh) | 帽依赖性内切核酸酶抑制剂及其用途 | |
| CN111183129A (zh) | 新型邻氨基苯甲酸系化合物、使用了该化合物的Pin1抑制剂、炎症性疾病及癌症的治疗剂 | |
| JPH11269140A (ja) | 分化誘導剤 | |
| KR20110136888A (ko) | 퀴녹살린 유도체 및 양성 및 악성 종양 질병 치료를 위한 이의 용도 | |
| TW201805271A (zh) | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 | |
| US8247439B2 (en) | Jasmonate derivatives, pharmaceutical compositions and methods of use thereof | |
| EP3481806B1 (en) | 4-anilino-quinoline compounds as anti-cancer agents | |
| KR20120074264A (ko) | 헤테로사이클릭 치환된 아카르다이트 유도체 및 그 용도 | |
| US9284274B2 (en) | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof | |
| CN110218202A (zh) | 一类n-苄基取代的氨基水杨酸2-坎醇酯的哌嗪衍生物及其药物用途 | |
| CN113845484B (zh) | 喹唑啉类小分子抑制剂及其在抗肿瘤药物中的应用 | |
| EP4442684A1 (en) | A class of pyrimidine compounds, and preparation method therefor and use thereof | |
| CA2435399A1 (en) | New anthracene derivatives and their use as pharmaceutical preparations | |
| CN105017034B (zh) | 氨基醇类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| US20240139191A1 (en) | Small molecules as larp1 ligands | |
| EP3194360B1 (en) | 4-oxo-n-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer | |
| IL229418A (en) | Derivatives of gasmont, pharmaceutical preparations and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220816 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240715 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241008 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241008 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241223 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250421 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250422 |